GlaxoSmithKline to acquire oral care company Biotene

NEW YORK GlaxoSmithKline is buying rights to the dry-mouth drug Biotene from California drug maker Laclede, GSK has announced.

“The acquisition of Biotene extends our portfolio in therapeutic oral health care to include a proven treatment for dry mouth,” GSK Consumer Healthcare president John Clarke said in a statement. “This opportunity leverages our global capability with dental and medical professionals and is a further step towards our goal in GSK of building and growing a diversified healthcare business.” 

Biotene generated $50 million in sales for Laclede last year, according to GSK.